Do you routinely consider ACPA status in your choice of Biologic MOA?

#ACR19 @rheumnow L20 head-to-head IXE vs ADA PSA 52wk trial: IXE shows significantly ⬆️ response than ADA for simultaneous ACR50 + PASI100 through Wk 52.TEAEs in 73.9% IXE &68.6% ADA pts. sAEs in 4.2% IXE&12.4% ADA pts, and d/c 2/2 AEs in 4.2% IXE & 7.4% ADApts; no deaths https://t.co/WeGdmu0vh6

#ACR19 RITAZAREM RCT rituxan vs imuran, AAV maintenance RTX superior to imuran w/HR 0.36 and relapse rate at 24 months (13% vs 38% imuran, NNT=4). Hypogam risk only 4% higher vs imuran (NNH~25) and non-severe infections similar Supports guideline recs from this AM! @RheumNow https://t.co/m9FkJ7d7I9

#ACR19 @RheumNow FINCH1 results for filgotinib in RA w/MTX inadequate response Good efficacy over PLBO for ACR50 at 24 wks (NNT~4), somewhat less impressive than UPA against TNF (NNT~20, not superior) Lower rates of HSV! Also, like UPA there is (as yet) no VTE signal https://t.co/1HjFgfXvlX

J Stone IgG4-RD pearl: If elevated at baseline the serum IgG4 is a good biomarker for IgG4-RD. If very high, IgG4, can be a marker for recurrent disease. Hypocomplementemia implies renal involvement. #ACR2018 @RheumNow

Ixekizumab is a high-affinity monoclonal antibody against interleukin-17A. In patients with psoriatic arthritis, ixekizumab was better than adalimumab in treating skin disease (PASI 100). Similar improvements in joint disease (ACR20/50/70). Dr. Josef Smolen #ACR19 @RheumNow https://t.co/BriY8o10Hq

In patients with Sjogren's, Ianalumab, a dual-mode of action biologic combining BAFF receptor inhibition with B cell depletion, showed significant response in ESSDAI, a disease activity index, but did not seem to improve most PROs such as fatigue #ACR19 @RheumNow https://t.co/l5UFwOjt2C

Abstr# 2440: Strong association between psoriatic arthritis and osteoporosis (45%) and osteopenia (13%). A good reminder to screen these patients to avoid complications of these additional comorbidities. #ACR19 @RheumNow https://t.co/0RvJtYCYJl

Abstr# 2137: Patient with metastatic melanoma who develop PD-1 inhibitor related inflammatory arthritis have significantly improved survival. Although checkpoint inibitors are associated with autoimmune side effects, often suggests a better cancer prognosis. #ACR19 @RheumNow https://t.co/geTUO2yLJX

It was such a pleasure to interview ACR Master Dr. John Reveille! He spoke about how the field has changed, what he looks forward to at #ACR19, and he even gave us a preview of his Hench lecture! @rheumnow @UTHealth https://t.co/JwIOWmBA4x via @YouTube

• Dr. Kanika Monga Interviews Dr. John Reveille - YouTube

SLE has high work disability. Interestingly work disability was not high in some organ systems such as renal but mild GN or CRF may not be symptomatic. Fibromyalgia, low education, low SED and older age increase work disability ACR219 @RheumNow abstr 1578 https://t.co/DdHgluRPIV

Anifrolumab, a type I IFN receptor antagonist, was effective in patients with SLE to increase BICLA response versus placebo. Results of the TULIP-2 trial. #ACR19 @RheumNow

J Stone GCA pearls: Dry cough can be a symptom of occult GCA. Jaw claudication comes on quickly. Predicts +ve TAB. Tongue ulcers in GCA occur on the lat. part of the mid tongue. This is a watershed area for blood supply. Strawberry gums can be seen in GCA. #ACR19 @RheumNow

“TULIP-2 was a positive phase 3 trial in lupus, and there haven’t been many times before that those words have been spoken” - @EricFMorand Anifrolumab in mod-severe SLE #ACR19 L17 @RheumNow @US_FDA https://t.co/8lqBmaWHW0

Telitacicept is a recombinant fusion protein with the extracellular domain of TACI and the FC domain of human IgG1. #ACR19 @RheumNow